AstraZeneca's Calquence gains FDA approval for untreated mantle cell lymphoma, supported by data showing improved survival and reduced disease progression.

Benzinga

New York

United States

FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma - AstraZeneca (NASDAQ:AZN)

Ad Fontes Media

Media Bias/Fact Check

AstraZeneca’s Calquence Gains U.S. Approval for First-Line Treatment of Mantle Cell Lymphoma, Following Positive Phase III Results (IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation. The approval is based on positive results from the ECHO Ph…

EuropaWire.eu

AstraZeneca’s Calquence Gains U.S. Approval for First-Line Treatment of Mantle Cell Lymphoma, Following Positive Phase III Results

AstraZeneca’s Calquence has expanded its FDA approval to include first-line treatment of mantle cell lymphoma. The regulatory decision makes Calquence the first BTK inhibitor approved as an initial treatment for this type of blood cancer. The post FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer appeared first on MedCity News.

MedCity News

FDA Nod Paves Way for AstraZeneca Drug to Become New Standard of Care in Rare Blood Cancer

Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line treatment of MCL in the US WILMINGTON, DE, USA I January 17, 2025 I AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab has been approved in the US for the treatment of adult patients with previously untreated mantle …

pipelinereview

CALQUENCE® (acalabrutinib) plus chemoimmunotherapy approved in the US for patients with previously untreated mantle cell lymphoma - Pipelinereview

The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of breast cancer, the health regulator said on Frida....
View detail at: US FDA approves AstraZeneca's drug for breast cancer)

tuoitrenews.vn

US FDA approves AstraZeneca's drug for breast cancer

AstraZeneca’s Calquence became the first BTK inhibitor approved in the US for first-line use in mantle cell lymphoma on Thursday. The drug may now be used in combination with chemoimmunotherapy in ...

Endpoints News

AstraZeneca wins BTK race to market in first-line mantle cell lymphoma

Acalabrutinib with bendamustine and rituximab shows efficacy in patients with untreated mantel cell lymphoma by increasing progression-free survival in the ECHO trial.

Pharmacy Times

FDA Approves Acalabrutinib With Bendamustine, Rituximab For Patients With Previously Untreated Mantle Cell Lymphoma

AstraZeneca's BTK inhibitor Calquence is the first drug in the class to be approved in the US for first-line treatment of mantle cell lymphoma.

FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma - AstraZeneca (NASDAQ:AZN)

Coverage Details

Bias Distribution

Ownership

Similar News Topics

Similar News Topics